ACU-026-001 clinical trials
How each study uses ACU-026-001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ACU-026-001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- ACU-026-001-1
- 2
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Duke University (1)
Often tested with
Tested in the same studies.
Aluminum sulfate (1) · Aluminium sulfate (1) · DV901 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test ACU-026-001.
- Dec 2026Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIVPhase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- Oct 2027Pancoronavirus Vaccine Study in Healthy Adults Ages 18-55Phase 1 · Duke University
Studies
Open first, then newest update. How each study uses ACU-026-001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Pancoronavirus Vaccine Study in Healthy Adults Ages 18-55Not yet recruitingPhase 1Duke UniversityNCT07902583Written as ACU-026-001-1
- Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy AdultsRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07757802Written as ACU-026-001-1
- Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIVActive, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05903339Written as ACU-026-001-1 2.0mg